Glaxosmithkline Phar - Quarterly Results
11th Nov 2022
The revenue declined to Rs. 9056.10 millions for the quarter ended September 2022 as compared to Rs. 9157.70 millions during the corresponding quarter last year.Profit after tax improved marginally to Rs. 1935.60 millions for the quarter ended September 2022 from Rs. 1875.60 millions of corresponding previous quarter.The company reported a good operating profit of 2790.80 millions compared to 2690.50 millions of corresponding previous quarter.
| | Quarter ended | Year to Date | Year ended |
| | 202209 | 202109 | % Var | 202209 | 202109 | % Var | 202203 | 202103 | % Var |
| Sales | 9056.10 | 9157.70 | -1.11 | 16350.70 | 16176.10 | 1.08 | 32175.10 | 29204.70 | 10.17 |
| Other Income | 221.60 | 150.50 | 47.24 | 499.50 | 467.80 | 6.78 | 762.20 | 1101.90 | -30.83 |
| PBIDT | 2790.80 | 2690.50 | 3.73 | 4548.00 | 4325.20 | 5.15 | 8320.50 | 7079.60 | 17.53 |
| Interest | 3.90 | 3.50 | 11.43 | 10.70 | 11.40 | -6.14 | 19.90 | 35.30 | -43.63 |
| PBDT | 2786.90 | 2687.00 | 3.72 | 4537.30 | 4313.80 | 5.18 | 8416.40 | 5318.30 | 58.25 |
| Depreciation | 163.60 | 174.30 | -6.14 | 321.80 | 349.70 | -7.98 | 681.90 | 786.00 | -13.24 |
| PBT | 2623.30 | 2512.70 | 4.40 | 4215.50 | 3964.10 | 6.34 | 7734.50 | 4532.30 | 70.65 |
| TAX | 687.70 | 637.10 | 7.94 | 1123.60 | 1022.50 | 9.89 | 3968.70 | 1665.40 | 138.30 |
| Deferred Tax | -46.30 | -37.80 | 22.49 | -81.00 | -72.60 | 11.57 | -105.00 | 78.70 | -233.42 |
| PAT | 1935.60 | 1875.60 | 3.20 | 3091.90 | 2941.60 | 5.11 | 3765.80 | 2866.90 | 31.35 |
| Equity | 1694.10 | 1694.10 | 0.00 | 1694.10 | 1694.10 | 0.00 | 1694.10 | 1694.10 | 0.00 |
| PBIDTM(%) | 30.82 | 29.38 | 4.89 | 27.82 | 26.74 | 4.03 | 25.86 | 24.24 | 6.68 |